NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in ...
With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...
Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...
US pharma major Bristol Myers Squibb has announced that the Phase II TRANSCEND FL trial evaluating Breyanzi (lisocabtagene ...
Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...
A new treatment, lisocabtagene maraleucel, has been approved for NHS use, benefiting hundreds of blood cancer patients in England.
Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback